Bristol-Myers Squibb partners with Xencor to extend COVID-19 antibody half...

CompilationFan Dongdong

A few days ago, Xencor and Bristol Myers Squibb (Bristol Myers Squibb) signed a license agreement for the use of Xtend XmAb technology.

Bristol-Myers Squibb’s progress in the treatment of COVID-19 has been relatively slow.

SARS-CoV-2 mAb Duo was originally discovered by researchers at Rockefeller University.

Bristol-Myers Squibb plans to quickly enter the registration study after the completion of the first phase.

According to the terms of the agreement, Bristol-Myers Squibb will be solely responsible for supporting and advancing the research, development, regulatory application and commercial activities of SARS-CoV-2 mAb Duo.

The progress of the Bristol-Myers Squibb antibody portfolio is far behind that of companies such as Eli Lilly and Regeneron, which have similar treatment methods.

The FDA also revoked the emergency use authorization of bamlanivimab monotherapy.

Reference source:

1.